GNI F351IR!! Looking forward to the results in 2024!!

(Disclosed information progress) Announcement of the start of Phase III clinical trials (subject registration) for F351 in China Today, we would like to inform you that we have initiated the first subject registration in the Phase III clinical trial of the F351 candidate for the treatment of liver fibrosis caused by hepatitis B in China. Dr. In Luo, President and Chief Executive Officer of the Company, stated, "Progression from liver fibrosis to cirrhosis means a decrease in survival rates and an increased likelihood of progression to hepatocellular carcinoma, and preventing this remains one of the major unmet medical needs worldwide where no treatment has been found. The start of this trial represents a very important step in delivering a new drug to patients with liver disease following the favorable results of the Phase II trial."